Cardiology Updates by Xagena

Aprile 24, 2018Aprile 24, 2018

CardiologyOnline.net :: Cardiology

Cardiology Online, Cardiology Xagena, Cardiology Newsletter, Cardiology News, Updates in cardiology, Aggiornamento in Medicina, Cardiovascular Drugs :: Updates, Cancer Drugs :: Updates,

Brilinta Antiplatelet agents: Brilinta first to show reduction in …	Clinical outcomes according to … Clinical outcomes according to QRS duration and morphology …
Cordarone Atrial fibrillation: Betapace less effient than Cordarone for …	Lower dose beta-blocker … Lower dose beta-blocker therapy is … therapy will be associated …
Crestor Crestor may reverse atherosclerosis in patients with …	Angiox Myocardial infarction: Heparin rather than Bivalirudin after …
Angiomax Angiomax alone reduces a significant number of major …	Acute myocardial infarction … Acute myocardial infarction: Cyclosporine, an …
Patients with ST-segment … Patients with ST-segment elevation myocardial infarction …	Treatment of heart failure: the … Treatment of heart failure: the path to Entresto, an … to an …
Altri risultati in cardiologyonline.net »

Medical Updates

Aprile 21, 2018

Medicina

Updates in Internal Medicine

Advances and updates in Internal Medicine by Xagena – Xagena Medical News

Hypertension: efficacy and safety of Valsartan and Nebivolol as fixed-dose combination

The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood pressure than a dose increase of component monotherapy. Researc …

Melanoma treated with the anti-PD-1 monoclonal antibody Pembrolizumab: clinical efficacy and correlation with tumor PD-L1 expression

Pembrolizumab ( MK-3475 ) has demonstrated antitumor activity and acceptable safety in a phase I melanoma cohort. Researchers have provided updated efficacy data and correlation with tumor PD-L1 exp …

FDA: no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication Olmesartan in patients with diabetes

The FDA ( Food and Drug Administration ) has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication Olmesart …

Pooled analysis of LUX-Lung 3 and LUX-Lung 6 comparing Afatinib with chemotherapy: overall survival in patients with advanced non-small cell lung cancer harboring common EGFR mutations

Afatinib ( Giotrif ) is an oral, irreversible ErbB family blocker of EGFR, HER2, ErbB3 and ErbB4 signalling. LUX-Lung 3 ( LL3 ) has compared Afatinib with Cisplatin / Pemetrexed in 345 patients recrui …

Cardiology Updates by Xagena

Aprile 19, 2018Aprile 19, 2018

Medicina

Updates in Cardiology

Top News / Myocardial infarction: Heparin vs Bivalirudin

–

” Even if Heparin alone had produced statistically similar outcomes to Bivalirudin, it would have been a win for Heparin. A drug that costs less than a 1/400th of another that has similar efficacy and safety ought to be used preferentially “ Peter Berger and James Blankenship of Geisinger Health System, in Pennsylvania, USA

Myocardial infarction: Heparin rather than Bivalirudin after primary percutaneous coronary intervention can improve outcomes and save health budgets millions

A new study has compared outcomes for two drugs used to prevent blood clot formation during emergency myocardial infarction treatment. The study suggests that use of one of the drugs, Heparin, could …

Focus On: Diabetes mellitus & Heart failure

Sitagliptin therapy has shown no sign of increasing risk for all-cause hospitalization or death ( primary end point ), but the use of Sitagliptin was associated with greater risk of hospitalization for heart failure

Sitagliptin linked to increased risk of heart failure-related hospitalizations among patients with type 2 diabetes with pre-existing heart failure

The study objective was to evaluate the effects of Sitagliptin ( Januvia ), a dipeptidyl peptidase 4 inhibitor, in patients with type 2 diabetes ( T2D ) and heart failure ( HF ). There is uncertain …

News

Benefits of percutaneous MitraClip device for mitral regurgitation in high-surgical-risk patients: EVEREST II trial

The EVEREST II ( Endovascular Valve Edge-to-Edge REpair Study ) High-Risk registry and REALISM Continued Access Study High-Risk Arm are prospective registries of patients who received the MitraClip de …

Nonselective agents with greater inhibition of Cox-1 than Cox-2, such as Ibuprofen, were not associated with increased cardiovascular risk

Conclusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs ( NSAIDs ) are sparse. It has been hypothesized that regular NSAID use is associated with increased risk for cardi …

High-potency statin reduces mortality in survivors of an acute myocardial infarction

A study has determined all-cause mortality in patients with a first myocardial infarct who were treated with Simvastatin ( Zocor ) compared with high-potency statin and Simvastatin / Ezetimibe